ACR Convergence 2023: Do Not Miss – Rheumatoid arthritis I – Clinical (non-therapeutic)

Sytske Anne Bergstra
Sytske Anne is a post-doctoral researcher at the department of rheumatology of the Leiden University Medical Center and the project coordinator of the METEOR registry. Her main interests are rheumatoid arthritis, methodology, real world data and international comparisons.  Sytske Anne is a member of the Social Media Sub-Committee.

Poster 0121 | Sunday, 12.11.23 09:00
Epidemiology & Public Health Poster I
Author: Yee, J (USA)
Title: HIGH PREVALENCE OF MENTAL HEALTH DISORDERS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS

RA patients have a higher prevalence of depression (24% vs 12%), anxiety (21% vs 11%) and PTS (4% vs 2%) than matched controls. This may complicate care and treatment of these patients.
Oral 0769 | Sunday, 12.11.23 14:00
Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: RA-ILD
Author: Wheeler, A (USA)
Title: DEVELOPMENT AND VALIDATION OF A COMBINED CLINICAL AND GENETIC RISK SCORE FOR INSTERSTITIAL LUNG DISEAE IN A LARGE, MULTICENTER, PROSPECTIVE RHEUMATOID ARTHRITIS COHORT

A combined risk score including multiple genetic risk variants discriminated ILD in a large, multicentre RA cohort better than established clinical risk factors alone.
Poster 1273 | Monday, 13.11.23 09:00
RA – Diagnosis, Manifestations, and Outcomes Poster II
Author: Heckert, S (Netherlands)
Title: LONG-TERM FOLLOW-UP OF TREATED-TO-TARGET RA AND UA: RESULTS OF THE BeSt AND IMPROVED STUDIES

Long-term extension data after 20 and 12 years of two treat-to-target trials showed that 91% of patients were in remission or low disease activity, with low HAQ (0.75 and 0.50), but clinically significant SHS progression of median 11 and 6 points.
Oral 1627 | Monday, 13.11.23 14:00
Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Comorbidities
Author: Karpouzas, G (Canada)
Title: METHOTREXATE USE ASSOCIATES WITH ISCHEMIC CARDIOVASCULAR RISK REDUCTION IN MALES BUT NOT FEMALES WITH RHEUMATOID ARTHRITIS
Methotrexate may decrease cardiovascular risk in RA patients. This study shows that baseline methotrexate use was associated with a lower risk of MACE and all ischaemic CVE in males, but not in females.
Poster 2104 | Tuesday, 14.11.23 09:00
RA – Diagnosis, Manifestations, and Outcomes Poster III
Author: Sobue,Y (Japan)
Title: RELATIONSHIP BETWEEN FRAILTY AND LARGE JOINT SYMPTOMS IN RHEUMATOID ARTHRITIS PATIENTS

The involvement of one or more large joints in RA indicates a high possibility of frailty, with the largest effect for the knee and ankle joints.
Oral 2480 | Tuesday, 14.11.23 14:00
Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes
Author: Konzett, V (Denmark)
Title: DEFINITION OF RHEUMATOID ARTHRITIS FLARE BASED ON SDAI AND CDAI

This study provides novel preliminary definitions for flare in RA based on changes in SDAI and CDAI, which could be used to assess flare rates after treatment tapering or withdrawal.

Leave a Reply